Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Boehringer Ingelheim
Boehringer Ingelheim
Boehringer Ingelheim latest drugmaker to limit 340B discounts
Beckers Hospital Review
Wed, 07/7/21 - 10:27 pm
Boehringer Ingelheim
340B
Eli Lilly, Boehringer Ingelheim tout pivotal heart failure win for Jardiance, potentially setting up a Novartis showdown
Endpoints
Tue, 07/6/21 - 10:52 am
Eli Lilly
Boehringer Ingelheim
heart failure
clinical trials
Jardiance
Farxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s Jardiance
Pharmaforum
Wed, 06/23/21 - 10:59 am
AstraZeneca
Farxiga
heart failure
Boehringer Ingelheim
Eli Lilly
Jardiance
Boehringer, Lilly and Takeda join matchmaker PharmStars' digital health accelerator
Fierce Pharma
Wed, 06/16/21 - 11:50 am
PharmStars
digital health
accelerators
Takeda
Eli Lilly
Boehringer Ingelheim
ASCO: Boehringer, OSE offer promising glimpse of the immuno-oncology drug at the heart of their $1.4B deal
Fierce Biotech
Fri, 05/21/21 - 11:52 am
Boehringer Ingelheim
OSE Immunotherapeutics
immuno-oncology
BI 765063
ASCO 2021
The retreat of corporate venture funding?
EP Vantage
Fri, 04/23/21 - 11:02 am
funding
venture funding
venture capital
AbbVie
Amgen
Boehringer Ingelheim
Bristol Myers Squibb
Eli Lilly
GSK
JNJ
Merck
Merck KGaA
Pfizer
Roche
Sanofi
Takeda
Boehringer and MD Anderson extend KRAS cancer collaboration
Pharmaforum
Wed, 04/14/21 - 09:39 pm
Boehringer Ingelheim
MD Anderson
KRAS
cancer
Boehringer’s big cancer reveal draws near
EP Vantage
Mon, 03/29/21 - 10:27 am
Boehringer Ingelheim
AACR
cancer
oncology
KRAS
COVID-19 drives Boehringer’s R&D spend to record level in 2020
Pharmaforum
Thu, 03/25/21 - 11:49 am
Boehringer Ingelheim
R&D
COVID-19
Boehringer Ingelheim, Gubra to validate new Peptides for obesity
Pharmaceutical Business Review
Tue, 03/2/21 - 10:47 am
Boehringer Ingelheim
Gubra
peptides
obesity
JPM: Boehringer inks Enara deal to source 'dark antigens' for cancer immunotherapies
Fierce Biotech
Tue, 01/12/21 - 11:00 am
JPMHC 2021
Boehringer Ingelheim
Enara Bio
dark antigens
cancer
cancer vaccines
Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure label
Pharmaforum
Tue, 01/12/21 - 10:50 am
Boehringer Ingelheim
Eli Lilly
Jardiance
FDA
heart failure
fast track
Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race
Fierce Biotech
Thu, 12/10/20 - 11:27 am
Boehringer Ingelheim
NBE Therapeutics
M&A
Merck
antibody-drug conjugate
ROR1
Citing toxicity concerns, Boehringer Ingelheim drops short-lived IPF pact — keeping $1B+ in its pocket
Endpoints
Wed, 11/11/20 - 11:07 am
Boehringer Ingelheim
IPF
Bridge Biotherapeutics
BBT-877
Boehringer, Yale trial digital tech in heart failure
Pharmaforum
Fri, 10/16/20 - 11:08 am
Boehringer Ingelheim
Yale
digital therapeutics
digital health
heart failure
Boehringer hopes schizophrenia apps will Click into place
EP Vantage
Tue, 09/15/20 - 10:49 am
digital therapeutics
Boehringer Ingelheim
Click Therapeutics
schizophrenia
CT-155
After Novartis left, Boehringer bets up to $500M on the field of prescription smartphone app
Endpoints
Fri, 09/11/20 - 10:44 am
Boehringer Ingelheim
digital therapeutics
Click Therapeutics
mobile apps
Novartis
ESC 2020 – Jardiance joins Farxiga in showing heart failure benefit
EP Vantage
Mon, 08/31/20 - 10:13 am
ESC
Eli Lilly
Boehringer Ingelheim
Farxiga
Jardiance
heart failure
AstraZeneca
Boehringer calls off €627M deal with GSK spinout, passing on schizophrenia drug option
Endpoints
Wed, 08/26/20 - 11:09 am
Boehringer Ingelheim
GSK
schizophrenia
Autifony
AUT00206
Boehringer Ingelheim to Pay $379,000 to Settle Wage Discrimination Charges
BioSpace
Fri, 08/21/20 - 11:38 pm
Boehringer Ingelheim
gender discrimination
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
…
next ›
last »